Skip to main content

Outlook Therapeutics, Inc.

corporate_fare Company Profile

Outlook Therapeutics, Inc.

OTLK·NASDAQ·Life Sciences·CIK 0001649989

This biopharmaceutical company develops ONS-5010/LYTENAVA, an ophthalmic formulation of bevacizumab. This product is approved by the European Commission in the European Union and the Medicines and Healthcare products Regulatory Agency in the United Kingdom for treating wet age-related macular degeneration (wet AMD) in adults. The company launched ONS-5010/LYTENAVA directly into Germany and the UK in June 2025. A Biologics License Application for ONS-5010/LYTENAVA for wet AMD treatment is currently under review by the U.S. Food and Drug Administration. The company aims to launch directly in the United States if approved. It may also seek approval for ONS-5010/LYTENAVA in other markets. ONS-5010/LYTENAVA is manufactured in the United States. Bevacizumab is a full-length, humanized anti-VEGF recombinant monoclonal antibody that inhibits VEGF and associated angiogenic activity. Before ONS-5010/LYTENAVA's approval in the EU and UK, bevacizumab was only approved for various cancer treatments and not optimized for retina diseases. The company submitted standard biologic therapeutic applications for ONS-5010/LYTENAVA, not using the biosimilar drug regulatory pathway, as bevacizumab was not an approved drug for retinal diseases in the United States and other major markets. Off-label repackaged bevacizumab is a frequently used first-line anti-VEGF treatment, with approximately 2.8 million injections annually in Europe and approximately 2.7 million injections annually in the United States.

Outlook Therapeutics, Inc. (NASDAQ:OTLK) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 60 items for OTLK at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-09-30, rated 8/10. Across its 20 most recent items scored 7 or higher, the top rating is 10/10, with 13 rated 8 or above. Recent SEC coverage for OTLK spans 8-K, 10-Q, SCHEDULE 13D/A, 4.

Recent high-impact activity:

  • Outlook Therapeutics Receives Nasdaq Bid-Price Deficiency Notice, Must Regain $1.00 by March 24, 2027
  • Outlook Therapeutics Sets $485 Per Vial Wholesale Price for LYTENAVA
  • Outlook Therapeutics Q3 10-Q: Going Concern Warning and $51M Dilutive Offering
  • Outlook Therapeutics Plans $55M Offering at $0.99 to Fund LYTENAVA Launch
  • GMS Ventures Invests $2.5M in Outlook Therapeutics' $55M Offering

Financial Snapshot

Fiscal year ended September 30, 2025
Revenue
$1.41M
Net Income
-$62.42M
Diluted EPS
-$1.79
Op. Cash Flow
-$51.83M
Gross Profit
$57.2K
Operating Income
-$67.06M
Cash & Equivalents
$8.08M
Debt / Equity
0.00×
Net Margin
-44.16×
Shares Outstanding
53.89M sh
Source: 10-K · filed 2025-12-19 · accession 0001104659-25-123264

Short Interest & Short Volume

10.10 days to cover

FINRA reported short interest of 35,546,027 shares in OTLK as of the October 30, 2026 settlement, a 9.1% increase from the prior period — about 10.1 days to cover at its recent average daily volume. On November 20, 2026, 50.4% of OTLK volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)35,546,027 shares as of October 30, 2026
Change vs prior period▲ 9.1%
Days to cover10.10 at avg daily volume of 3,518,818
Daily short volume (FINRA facilities)50.4% of 3,400,867 shares on November 20, 2026
5-day average short volume47.7%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Dilution Risk

Moderate risk

Filing-implied dilution signals for OTLK, detected from its recent SEC filings · based on capital-structure filings through 2026-08-14.

2 recent capital raisesATM program1 shelf registration

Public Offering Priced · Net Proceeds and Use

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Browse all tickers starting with O →
$0.3801 -2.54% today
52-week range · as of 2026-09-30 $0.1611 – $2.54
Market cap
$94.94M
Volume
5.2M (1.4× avg)
3-mo avg 3.7M
Live data · 2026-11-22 12:43 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed OTLK - Latest Insights

OTLK
Sep 30, 2026, 4:30 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.5989
Real-time Price: $0.3801 info
Change: -$0.2188 (-37%) info
Market Cap: $94.945M info
OTLK
Sep 18, 2026, 4:30 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.670776
Real-time Price: $0.3801 info
Change: -$0.290676 (-43%) info
Market Cap: $94.945M info
OTLK
Aug 18, 2026, 5:29 PM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $0.6982
Real-time Price: $0.3801 info
Change: -$0.3181 (-46%) info
Market Cap: $94.945M info
OTLK
Aug 17, 2026, 7:27 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $0.7973
Real-time Price: $0.3801 info
Change: -$0.4172 (-52%) info
Market Cap: $94.945M info
OTLK
Aug 14, 2026, 7:54 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
7
Price at Filing: $0.790
Real-time Price: $0.3801 info
Change: -$0.4099 (-52%) info
Market Cap: $94.945M info
OTLK
Aug 14, 2026, 7:52 PM EDT
Filing Type: 4
Importance Score:
8
Price at Filing: $0.762
Real-time Price: $0.3801 info
Change: -$0.3819 (-50%) info
Market Cap: $94.945M info
OTLK
Aug 14, 2026, 8:36 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.8499
Real-time Price: $0.3801 info
Change: -$0.4698 (-55%) info
Market Cap: $94.945M info
OTLK
Aug 14, 2026, 8:30 AM EDT
Filing Type: 424B5
Importance Score:
8
Price at Filing: $0.8413
Real-time Price: $0.3801 info
Change: -$0.4612 (-55%) info
Market Cap: $94.945M info
OTLK
Aug 14, 2026, 8:00 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.858
Real-time Price: $0.3801 info
Change: -$0.4779 (-56%) info
Market Cap: $94.945M info
OTLK
Aug 12, 2026, 9:45 PM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $0.930
Real-time Price: $0.3801 info
Change: -$0.5499 (-59%) info
Market Cap: $94.945M info
OTLK
Aug 12, 2026, 5:13 PM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $0.940
Real-time Price: $0.3801 info
Change: -$0.5599 (-60%) info
Market Cap: $94.945M info
OTLK
Aug 12, 2026, 4:49 PM EDT
Filing Type: 424B5
Importance Score:
8
Price at Filing: $0.910
Real-time Price: $0.3801 info
Change: -$0.5299 (-58%) info
Market Cap: $94.945M info
OTLK
Aug 12, 2026, 4:01 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.940
Real-time Price: $0.3801 info
Change: -$0.5599 (-60%) info
Market Cap: $94.945M info
OTLK
Jul 24, 2026, 5:02 PM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $1.38
Real-time Price: $0.3801 info
Change: -$0.9999 (-72%) info
Market Cap: $94.945M info
OTLK
Jul 24, 2026, 5:01 PM EDT
Filing Type: 8-K
Importance Score:
10
Price at Filing: $1.40
Real-time Price: $0.3801 info
Change: -$1.02 (-73%) info
Market Cap: $94.945M info
OTLK
Jul 24, 2026, 2:43 PM EDT
Source: Reuters
Importance Score:
10
Price at Filing: $1.64
Real-time Price: $0.3801 info
Change: -$1.25 (-77%) info
Market Cap: $94.945M info
OTLK
Jul 23, 2026, 7:54 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.37
Real-time Price: $0.3801 info
Change: -$0.9899 (-72%) info
Market Cap: $94.945M info
OTLK
Jul 21, 2026, 4:37 PM EDT
Filing Type: 424B3
Importance Score:
7
Price at Filing: $1.42
Real-time Price: $0.3801 info
Change: -$1.04 (-73%) info
Market Cap: $94.945M info
OTLK
Jul 17, 2026, 4:05 PM EDT
Filing Type: S-3
Importance Score:
7
Price at Filing: $1.40
Real-time Price: $0.3801 info
Change: -$1.02 (-73%) info
Market Cap: $94.945M info
OTLK
Jul 16, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $1.49
Real-time Price: $0.3801 info
Change: -$1.11 (-74%) info
Market Cap: $94.945M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets